Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

@article{Geller2002PharmacokineticsAB,
  title={Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.},
  author={David E. Geller and William H Pitlick and Pasqua A Nardella and William G. Tracewell and Bonnie W Ramsey},
  journal={Chest},
  year={2002},
  volume={122 1},
  pages={219-26}
}
STUDY OBJECTIVES To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC Plus; Pari Respiratory; Richmond, VA) and a compressor (Pulmo-Aide, model 5650D; DeVilbiss Health Care; Somerset, PA) in cystic fibrosis (CF) patients during the pivotal phase III trials. DESIGN Data from two identical, 24-week, randomized, double-blind, placebo-controlled, parallel-group studies. SETTING US sites… CONTINUE READING